Observational studyInvestigational new drugs2023

Population Pharmacokinetics, Pharmacogenomics, and Adverse Events of Osimertinib and its Two Active Metabolites, AZ5104 and AZ7550, in Japanese Patients with Advanced Non-small Cell Lung Cancer: a Prospective Observational Study.

Emi Ishikawa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.